TRES GROSSE NEWS en EXCLU

Tous les sujets
    02/07/2026 17:07:44

    Certes.

    Mais à la montée, oui 🙃


    AMF : non, je ne suis pas actionnaire 😇

    0
    Répondre
    02/07/2026 17:00:49

    A la descente, on est souvent heureux de ne pas avoir à accompagner les moutons à l'abattoir…

    ; )

    0
    Répondre
    02/07/2026 16:52:28

    Ouaip.

    +40% le bidule.

    Je regrette de ne pas avoir eu une tête d’œuf à tondre 🙃

    1
    Répondre
    02/07/2026 16:44:13

    Concernant cette bouse… Encore un stupéfiant boursier qui devrait en plumer plus d'un…

    : (

    Note ABC Bourse : 3/20

    https://www.abcbourse.com/analyses/conseil/ALVIOp


    Visiblement, on sait même tondre les oeufs chez Valerio Therapeutics.


    Temporary transfer of Valerio Therapeutics shares to the Penalty Bench from 16 May 2025

    https://valeriotx.com/wp-content/uploads/2025/05/PressRelase_PenaltyBench_22052025_VTX_EN.pdf

    Paris (France), [22 May 2025] – Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) informs its shareholders that due to the delay in the publication of its 2024 annual financial report and in accordance with article 7.3.1 of the Euronext Growth Rules, Euronext has taken the decision to transfer the shares of Valerio Therapeutics to the Penalty Bench compartment with effect from 16 May 2025.

    The Company was informed of this decision by letter dated 14 May 2025. Removal from the Penalty Bench will be automatic once Valerio Therapeutics will have published its annual financial report for the year ended 31 December 2024.

    As a reminder, Valerio Therapeutics announced in a press release on 5 May 2025 that it was postponing the publication of its annual financial report due to accounting difficulties regarding its US subsidiary.

    Valerio Therapeutics will inform its shareholders as soon as possible of the new date of publication of the 2024 annual financial report and the definitive date of the General Meeting called to approve the accounts for the 2024 financial year.

    For more information, visit www.valeriotx.com.

    CONTACTS
    Valerio Therapeutics
    Investor Relations:
    [email protected] | +33 (0) 1 70 38 33 99

    0
    Répondre
    01/07/2026 09:26:01
    TRES GROSSE NEWS en EXCLU
    0
    Répondre

      Forum de discussion Général

      202607021707 1105650